Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial

Asselah T, Hezode C, Qaqish RB, Elkhashab M, Hassanein T, Papatheodoridis G, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. The Lancet Gastroenterology & Hepatology [Internet]. 2016;1(1):25 - 35. https://linkinghub.elsevier.com/retrieve/pii/S2468125316300012

Publication Type:

Journal Article

Authors:

Asselah, Tarik; Hezode, Christophe; Qaqish, Roula B; Elkhashab, Magdy; Hassanein, Tarek; Papatheodoridis, George; Feld, Jordan J; Moreno, Christophe; Zeuzem, Stefan; Ferenci, Peter; Yu, Yao; Redman, Rebecca; Pilot-Matias, Tami; Mobashery, Niloufar

Source:

The Lancet Gastroenterology & Hepatology, Volume 1, Issue 1, p.25 - 35 (2016)

URL:

https://linkinghub.elsevier.com/retrieve/pii/S2468125316300012

Cited On:

External Third-party Web Link:

https://linkinghub.elsevier.com/retrieve/pii/S2468125316300012

Export Citation:

RIS Format

Top